Cancer immunotherapy

Oxford BioTherapeutics (OBT) Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies from Boehringer Ingelheim (BI) Collaboration

Tuesday, March 31, 2020 - 1:00pm

OXFORD, United Kingdom and SAN JOSE, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, today announced that Boehringer Ingelheim has selected a second asset to advance into formal IND enabling studies.

Key Points: 
  • OXFORD, United Kingdom and SAN JOSE, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, today announced that Boehringer Ingelheim has selected a second asset to advance into formal IND enabling studies.
  • It is one of several assets that have emerged from OGAP including several assets in preclinical and clinical development by OBT.
  • OBT and BIs collaboration employs OBTs OGAP target discovery platform to identify novel drug discovery targets that can be substrates for innovative antibody-based therapeutics.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.

BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

Monday, March 30, 2020 - 1:00pm

Commencing the NDA rolling submission in China marks a significant milestone for BeyondSpring, bringing Plinabulin one step closer to commercialization to enhance the lives of cancer patients, said Dr. Lan Huang, BeyondSprings co-founder and CEO.

Key Points: 
  • Commencing the NDA rolling submission in China marks a significant milestone for BeyondSpring, bringing Plinabulin one step closer to commercialization to enhance the lives of cancer patients, said Dr. Lan Huang, BeyondSprings co-founder and CEO.
  • The Company expects to submit an NDA for the same indication to the U.S. Food and Drug Administration (FDA) in the second half of 2020.
  • BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway.
  • Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN).

PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update

Friday, March 27, 2020 - 8:15pm

PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune today announced its financial results for the full year ended December 31, 2019 and provided a business update.

Key Points: 
  • PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune today announced its financial results for the full year ended December 31, 2019 and provided a business update.
  • For the year ended December 31, 2019, the net loss was approximately $6.9 million, or $1.44 per basic and diluted share.
  • PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform.
  • PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers.

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Thursday, March 26, 2020 - 8:42pm

EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

Key Points: 
  • EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
  • Previously, the process to create an a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.
  • With a personalized cancer vaccine process under 4 weeks, we can safely create a vaccine to treat all stages of aggressive cancer including in the neoadjuvant, adjuvant and metastatic setting.
  • EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.

Scholar Rock Announces Publication in Science Translational Medicine of Preclinical Data Detailing a Potent and Selective Inhibitor of TGFβ1 Overcoming Primary Resistance to Checkpoint Inhibition

Thursday, March 26, 2020 - 11:30am

Selective inhibition of latent TGF1 activation with SRK-181 has demonstrated an improved safety profile as compared to pan-TGF inhibitors.

Key Points: 
  • Selective inhibition of latent TGF1 activation with SRK-181 has demonstrated an improved safety profile as compared to pan-TGF inhibitors.
  • SRK-181 is a potent and highly selective inhibitor of TGF1 activation and is an investigational product candidate being developed to overcome primary resistance to checkpoint inhibitor therapy, such as anti-PD-(L)1 antibodies.
  • TGF1 is the predominant TGF isoform expressed in many human tumors, particularly for those tumors where checkpoint therapies are currently approved.
  • By overcoming this immune cell exclusion, Scholar Rock believes SRK-181 has the potential to induce tumor regression when administered in combination with anti-PD-(L)1 therapy.

Society for Immunotherapy of Cancer Advocates for Expanded Access to Anti-IL-6 Therapies for Critically Ill Patients

Wednesday, March 25, 2020 - 10:00pm

MILWAUKEE, March 25, 2020 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) has released a statement advocating for expanded access to FDA-approved IL-6/IL-6R-blocking antibodies for critically ill patients with COVID-19-induced hypoxia.

Key Points: 
  • MILWAUKEE, March 25, 2020 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) has released a statement advocating for expanded access to FDA-approved IL-6/IL-6R-blocking antibodies for critically ill patients with COVID-19-induced hypoxia.
  • Two large-scale trials of IL-6-targeting therapies have recently been announced, further underscoring the need for access to these therapies.
  • About SITC Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology.
  • Learn more about SITC, our educational offerings and other resources at http://www.sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program

Wednesday, March 25, 2020 - 2:00pm

The decoy cell strategy (I-Cell, which means immune-training cells) has been conceptualized and developed by Sorrento scientists utilizing expertise acquired in the fight against cancer.

Key Points: 
  • The decoy cell strategy (I-Cell, which means immune-training cells) has been conceptualized and developed by Sorrento scientists utilizing expertise acquired in the fight against cancer.
  • After irradiation to prevent the replication of the cells, the cells can be administered by intramuscular injection as a vaccine.
  • Per the publication, the overall strategy to utilize a viral antigen-expressing, non-replicating cellular system as both a carrier, and as an immunogenic antigen-presenting platform is novel.
  • Sorrento has identified a leading infectious disease contract research organization to support the phase 1 clinical trial and accelerated timelines.

Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund

Wednesday, March 25, 2020 - 1:00pm

Repertoire Immune Medicines , a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a venture philanthropy vehicle focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D).

Key Points: 
  • Repertoire Immune Medicines , a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a venture philanthropy vehicle focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D).
  • We are excited by Repertoire Immune Medicines world-class team and believe the highly innovative platform can enable a range of different therapies to change the trajectory for people with T1D, said Katie Ellias, Managing Director at the JDRF T1D Fund.
  • Repertoire Immune Medicines was then formed by combining two Flagship companies the innovative and proprietary immune decoding platforms of Cogen Immune Medicines and the immuno-oncology platforms of Torque Therapeutics to create a fully integrated Immune Medicines company.
  • The JDRF T1D Fund ( www.t1dfund.org ) is a venture philanthropy fund accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic equity investments.

Biotech Brief: Why Oncolytic Viruses are Becoming a Potent Weapon Against Cancer

Tuesday, March 24, 2020 - 12:30pm

PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.

Key Points: 
  • PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.
  • These naturally occurring or modified viruses are a potent new weapon against cancer, according to recent reports on this growing market.
  • Oncolytic viruses are naturally occurring or genetically modified to target specific types of cancer cells.
  • The oncolytic viruses must be genetically stable and be incapable of reverting back to its wild-type form while replicating inside cancer cells.

Biotech Brief: Why Oncolytic Viruses are Becoming a Potent Weapon Against Cancer

Tuesday, March 24, 2020 - 12:30pm

PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.

Key Points: 
  • PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.
  • These naturally occurring or modified viruses are a potent new weapon against cancer, according to recent reports on this growing market.
  • Oncolytic viruses are naturally occurring or genetically modified to target specific types of cancer cells.
  • The oncolytic viruses must be genetically stable and be incapable of reverting back to its wild-type form while replicating inside cancer cells.